Genetics Institute Inc. (GENIZ)
Jeffrey Casdin of Merrill Lynch upgraded GENIZ to "buy" from "above average." The emergence of thrombopoietin (TPO) and the announcement of the American Cyanamid acquisition by American Home Products, which owns a majority stake in GENIZ, have contributed to a 30 percent decline in the biotech company's share price over the last four months, he said.